Borderline Findings in<i>O</i>-(2-[<sup>18</sup>F]-Fluoroethyl)-l-Tyrosine PET of Patients with Suspected Glioma Relapse: Role in Clinical Practice
One of the most common clinical indications for amino acid PET using the tracer <i>O</i>-(2-[<sup>18</sup>F]-fluoroethyl)-l-tyrosine (<sup>18</sup>F-FET) is the differentiation of tumor relapse from treatment-related changes in patients with gliomas. A subset of patients may present with an uptake of <sup>18</sup>F-FET close to recommended threshold values. The goal of this study was to investigate the frequency of borderline cases and the role of quantitative <sup>18</sup>F-FET PET parameters in this situation. <b>Methods:</b> We retrospectively identified 439 patients with pretreated gliomas who underwent <sup>18</sup>F-FET PET for suspected tumor relapse and in whom the final diagnoses were confirmed by histopathology (<i>n</i> = 175) or clinical course (<i>n</i> = 264). Two experienced nuclear medicine physicians, masked to the final diagnoses, evaluated visually the PET scans by consensus. The findings were classified into 3 categories: clearly positive findings, borderline findings, or clearly negative findings. The diagnostic performance of established <sup>18</sup>F-FET PET parameters (i.e., tumor-to-brain ratio [TBR], time-to-peak ratio, slope, intercept) was evaluated separately for these 3 groups using receiver operating characteristics analyses. <b>Results:</b> In the visual analysis, <sup>18</sup>F-FET uptake was classified as clearly negative in 67 patients (15%), clearly positive in 234 patients (53%), and borderline in 136 patients (31%), with averaged mean TBR values of 1.5, 2.3, and 1.9, respectively. Receiver operating characteristics analysis showed a high accuracy for TBR values in patients rated as clearly positive or negative in visual rating (area under curve [AUC], 0.84-0.86), whereas the diagnostic performance of TBR values in borderline cases according to visual analysis was significantly lower (AUC, <0.60). Using TBR values ± 10% above or below the cutoff values increased the AUC by approximately 10% (AUC, 0.82-0.84). <b>Conclusion:</b> A considerable number of patients may present with borderline findings in <sup>18</sup>F-FET PET. In these patients, quantitative parameters should be used with caution for decision-making. The use of TBR values above or below the range of the cutoff values ±10% may increase the reliability of quantitative parameters to differentiate between tumor relapse and treatment-related changes.
Authors
- Martin Köcher (ORCID: https://orcid.org/0000-0002-5674-9227)
- Michael Wollring (ORCID: https://orcid.org/0000-0003-2177-6708)
- Felix M. Mottaghy (ORCID: https://orcid.org/0000-0002-7212-6521)
- Michael Stoffel (ORCID: https://orcid.org/0000-0002-4699-5125)
- Marion Rapp (ORCID: https://orcid.org/0000-0003-2343-244X)
- Garry Ceccon
- Norbert Galldiks (ORCID: https://orcid.org/0000-0002-2485-1796)
- Christoph Lerche (ORCID: https://orcid.org/0000-0003-2749-2108)
- Karl‐Josef Langen (ORCID: https://orcid.org/0000-0003-1101-5075)
- Jurij Rosen (ORCID: https://orcid.org/0000-0003-4606-1602)
- Christian Filß (ORCID: https://orcid.org/0000-0002-9927-6335)
- Gabriele Stoffels (ORCID: https://orcid.org/0000-0001-7114-1941)
- Jan‐Michael Werner (ORCID: https://orcid.org/0000-0001-7147-4594)
- N. Jon Shah (ORCID: https://orcid.org/0000-0002-8151-6169)
- Elke Hattingen (ORCID: https://orcid.org/0000-0002-8392-9004)
- Joachim P. Steinbach (ORCID: https://orcid.org/0000-0002-4695-2483)
- Hans Clusmann (ORCID: https://orcid.org/0000-0001-8258-9346)
- Michael Sabel (ORCID: https://orcid.org/0009-0000-1485-7820)
- Philipp Lohmann (ORCID: https://orcid.org/0000-0002-5360-046X)
- Martin R. Weinzierl
- Hosai Noltemeier
Institutions
- Goethe University Frankfurt (DE)
- Forschungszentrum Jülich (DE)
- Maastricht University (NL)
- Helios Klinikum Krefeld (DE)
- University Hospital Frankfurt (DE)
- Jülich Aachen Research Alliance (DE)
- University Hospital Cologne (DE)
- Frankfurt Cancer Institute (DE)
- Heinrich Heine University Düsseldorf (DE)
- RWTH Aachen University (DE)
Publication Details
- Journal
- Journal of Nuclear Medicine
- Published
- 2025-01-16
- DOI
- https://doi.org/10.2967/jnumed.124.268768
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00